PARIS – A 16-gene expression test that Genomic Health developed in collaboration with Pfizer was able to determine in a validation study which clinically high-risk, stage III kidney cancer patients would experience recurrence following surgery.
Genomic Health Kidney Cancer Test Gauges Recurrence Risk in Study, Not Benefit to Pfizer's Sutent
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.